NTRA:NGS-Natera Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 143.94

Change

-4.36 (-2.94)%

Market Cap

USD 0.67B

Volume

1.26M

Analyst Target

USD 56.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Natera Inc is a diagnostics company with proprietary molecular and bioinformatics technology that it is deploying to change the management of genetic disease.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-28 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 33.82B
ICLR ICON PLC

N/A

USD 14.94B
ILMN Illumina Inc

N/A

USD 14.06B
MEDP Medpace Holdings Inc

N/A

USD 9.97B
EXAS EXACT Sciences Corporation

N/A

USD 8.47B
GH Guardant Health Inc

N/A

USD 4.85B
RDNT RadNet Inc

N/A

USD 3.68B
SHC Sotera Health Co

N/A

USD 3.23B
WGS GeneDx Holdings Corp.

N/A

USD 2.75B
VCYT Veracyte Inc

N/A

USD 2.48B

ETFs Containing NTRA

GN0M:XETRA Global X Genomics & Biote.. 6.31 % 0.00 %

N/A

USD 7.05M
GNOG:LSE Global X Genomics & Biote.. 6.29 % 0.00 %

N/A

USD 9.10M
GNOM:SW Global X Genomics & Biote.. 6.12 % 0.00 %

N/A

USD 8.06M
CURG:LSE VanEck Genomics and Healt.. 5.94 % 0.00 %

N/A

USD 5.16M
ARCG:LSE ARK Genomic Revolution UC.. 5.44 % 0.00 %

N/A

USD 9.51M
ARKG:LSE ARK Genomic Revolution UC.. 4.97 % 0.00 %

N/A

USD 9.33M
EKG First Trust Nasdaq Lux Di.. 4.95 % 0.00 %

N/A

USD 2.40M
CURE:XETRA VanEck Genomics and Healt.. 4.55 % 0.00 %

N/A

N/A
WRNA:XETRA WisdomTree BioRevolution .. 4.37 % 0.00 %

N/A

USD 2.77M
WBIO:LSE WisdomTree BioRevolution .. 4.29 % 0.00 %

N/A

USD 4.04M
BBH VanEck Biotech ETF 4.11 % 0.35 %

N/A

USD 0.40B
WDNA WisdomTree BioRevolution .. 4.08 % 0.00 %

N/A

USD 1.96M
AWEG The Alger ETF Trust 3.39 % 0.00 %

N/A

USD 4.73M
CURE:AU ETFS S&P Biotech ETF 2.33 % 0.00 %

N/A

USD 0.04B
WDNA:LSE WisdomTree BioRevolution .. 2.31 % 0.00 %

N/A

N/A
HEAL:SW iShares Healthcare Innova.. 2.10 % 0.00 %

N/A

USD 1.05B
IBB iShares Biotechnology ETF 1.86 % 0.47 %

N/A

USD 6.00B
XMLH:F Legal & General Ucits Etf.. 1.80 % 0.00 %

N/A

N/A
EQQJ:XETRA Invesco NASDAQ Next Gener.. 1.38 % 0.00 %

N/A

USD 0.05B
WOSC:SW SPDR® MSCI World Small C.. 0.25 % 0.00 %

N/A

USD 1.06B
ARKG ARK Genomic Revolution ET.. 0.00 % 0.75 %

N/A

USD 1.06B
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

N/A

CAD 0.01B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 0.66B
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

N/A

USD 0.11B
BTEC 0.00 % 0.42 %

N/A

N/A
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

N/A

CAD 0.01B
FSMD Fidelity Small-Mid Factor 0.00 % 0.00 %

N/A

USD 0.86B
VBK Vanguard Small-Cap Growth.. 0.00 % 0.07 %

N/A

USD 17.24B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

N/A

CAD 0.22B
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
IS0R:F iShares High Yield Corpor.. 0.00 % 0.00 %

N/A

N/A
ZPRS:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 0.83B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.05B
IS0R:XETRA iShares $ High Yield Corp.. 0.00 % 0.00 %

N/A

N/A
IUSN:XETRA iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
ZPRS:XETRA SPDR MSCI World Small Cap.. 0.00 % 0.00 %

N/A

N/A
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

N/A

N/A
BBMC JPMorgan BetaBuilders U.S.. 0.00 % 0.00 %

N/A

USD 1.80B
FRTY Alger Mid Cap 40 ETF 0.00 % 0.00 %

N/A

USD 0.09B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
ATFV Alger 35 ETF 0.00 % 0.00 %

N/A

USD 0.03B
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
DOCG:LSE L&G Healthcare Breakthrou.. 0.00 % 0.00 %

N/A

USD 0.06B
DOCT:LSE L&G Healthcare Breakthrou.. 0.00 % 0.00 %

N/A

USD 0.06B
CVRT Calamos ETF Trust 0.00 % 0.00 %

N/A

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.07% 65% D 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.07% 65% D 44% F
Trailing 12 Months  
Capital Gain 57.38% 85% B 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.38% 85% B 92% A
Trailing 5 Years  
Capital Gain 465.36% 100% F 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 465.36% 100% F 95% A
Average Annual (5 Year Horizon)  
Capital Gain 44.84% 83% B 87% B+
Dividend Return 44.84% 83% B 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 83.67% 40% F 24% F
Risk Adjusted Return 53.59% 94% A 80% B-
Market Capitalization 0.67B 98% N/A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 17.60 7% 7%
Price / Cash Flow Ratio 155.04 5% 1%
Price/Free Cash Flow Ratio -26.80 95% 95%
Management Effectiveness  
Return on Equity -19.42% 66% 44%
Return on Invested Capital -19.07% 61% 34%
Return on Assets -8.96% 61% 36%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.